SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Metas quarterly results, driven by strong advertising growth and an upbeat revenue outlook, have drawn attention, but traders are divided over whether that strength justifies the costly AI buildout. Concerns about negative free cash flow and the new non-voting share classs potential to fund spending have fueled skepticism despite bullish reactions to the results.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBMs quarterly results beat expectations, led by software growth and the closing of previously delayed deals, while the company raised its free-cash-flow outlook. Traders are split after an initial post-earnings surge faded: bulls cite the stronger results, while skeptics point to unchanged revenue guidance and flat consulting growth as reasons for a sell-the-news reaction.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Teslas quarterly results and earnings call are driving attention, with traders weighing an adjusted earnings and cash-flow beat against flat revenue, weaker operating profitability, and the companys heavy investment plans. Many focused on the post-report pullback and reduced capex guidance, while optimism around AI and autonomyand speculation about a possible SpaceX mergercompetes with concerns about execution and valuation.

Lam Research Corp. engages in the design, manufacture, marketing, refurbishment, and provision of semiconductor processing equipment used in the fabrication of integrated circuits. It operates through the following geographical segments: United States, China, Europe, Japan, Korea, Southeast Asia, and Taiwan. The company was founded by David K. Lam in 1980 and is headquartered in Fremont, CA.

Lam Research Corp.

Lam Researchs strong quarterly results were overshadowed by an outlook that traders viewed as merely in line or soft against elevated expectations, prompting a selloff. The debate is whether cleanroom and supply-chain constraints are only delaying AI- and memory-driven equipment demand, as dip buyers argue, or signal a more concerning slowdown.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Bitcoins rebound is driving renewed buying in Strategy as a leveraged BTC proxy, with bulls pointing to momentum and a possible short squeeze. The rally is contested by concerns over Bitcoin volatility, shareholder dilution and a potential MSCI index exclusion.

AEVEX Corp. operates as a holding company. It operates through Tactical Systems and Global Solutions segments. The Tactical Systems segment focuses on design, development, and production of autonomous systems including unmanned aerial systems and unmanned surface vessels. The Global Solutions segment offers services and mission support to defense and intelligence customers. The company was founded in 2017 and is headquartered in Solana Beach, CA.

AEVEX Corp. - Ordinary Shares - Class A

AEVEX Corp

A report that the U.S. Navy halted new orders for AEVEXs GARC drone boats over performance concerns sparked a sharp selloff. AEVEX disputes that orders were halted and says it fulfilled its delivery obligation, leaving traders divided between calling the drop an overreaction and worrying about future procurement and management credibility.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment includes To-Home businesses, which include Ele.me, local services and delivery platforms, and Taoxianda, and To-Destination segment businesses, which include Amap, the provider of mobile digital maps, navigation and real-time traffic information, and restaurant and local services guide platforms. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solutions. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba is drawing attention after falling alongside Chinese internet stocks as the Hang Seng Tech Index slipped below 4,000, despite gains in U.S. markets; traders point to broader China-market weakness rather than a clear company-specific trigger. The discussion is split between buyers calling the selloff oversold and expecting a rebound, and bearish traders warning that China-tech weakness and lingering economic concerns could prolong the decline.

Netlist, Inc. engages in the design, manufacture and sale of memory subsystems for the computing and communications markets. Its products include enterprise SSD, embedded flash, memory module, lightning DDR5 DIMM, SK hynix, AI server. The company was founded by Jayesh Bhakta, Chun Ki Hong and Christopher Lopes in June 2000 and is headquartered in Irvine, CA.

Netlist Inc

The USPTOs decision not to intervene in the Federal Circuit appeal over Netlists 912 patent claim 16after Samsung and Micron withdrew following settlementsis driving discussion. Traders disagree on whether the appeal could still lead to a remand or vacatur, or be dismissed as moot; the patent has not been restored, and any benefit to Netlists Google dispute remains uncertain.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

ARMs steep pullback and volatility are prompting debate over whether its valuation is too high amid weakness in AI and semiconductor stocks. Bears also cite the Qualcomm licensing dispute as a risk to future royalties, while bulls argue that demand for Arm-based CPUs in AI data centers supports the longer-term story.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

GLD is drawing attention for choppy, range-bound trading after a sharp gold pullback, with traders pointing to a stronger dollar, elevated Treasury yields, and inflation-driven rate concerns as headwinds. The community is divided between buyers treating the weakness as a support-holding opportunity and bears expecting further declines, while debate continues over golds safe-haven role.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care?

Novo's semaglutide expansion into liver disease and other obesity-related conditions can unlock growth, but competition and clinical risks loom.

Institutional Investors Are Loading Up on Madrigal Pharmaceuticals Stock. Should You?

Key PointsMadrigal's only commercial drug, Rezdiffra, continues to grow sales...

Here's Exactly What It Will Take for Madrigal Pharmaceuticals Stock to Take Off

Key PointsMASH cirrhosis could significantly expand Rezdiffra's addressable market...

Is Altimmune Worth Buying as Cash Rises but Execution Risks Linger?

ALT's stronger cash position supports pemvidutide's MASH, AUD and ALD programs, but long timelines, funding needs and competition remain risks.

MDGL Stock Down Despite Q2 Beat, MASH Drug Drives Top-Line Y/Y Growth

Madrigal beats Q2 estimates as Rezdiffra sales lift revenues 71% year over year, but shares fall as investors weigh slower commercial growth.

Madrigal (MDGL) Reports Q2 Loss, Beats Revenue Estimates

Madrigal (MDGL) delivered earnings and revenue surprises of +21.96% and +4.27%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Corcept Therapeutics (CORT) Q2 Earnings and Revenues Surpass Estimates

Corcept (CORT) delivered earnings and revenue surprises of +1,000.00% and +18.38%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

CMPS, MDGL, DFTX, GHRS, HELP Stocks In Spotlight Today – Why Wells Fargo Thinks Next Wave Of Depression Drugs Could Create New Winners

Equity

Wells Fargo began coverage on five biotech stocks on Monday, with only Compass Pathways receiving an ‘Equal-Weight’ rating while the rest received ‘Overweight’ ratings.


MDGL Stock In Focus — Retail Traders Buzz Over M&A Speculation And Fresh Patents For Liver Drug

Madrigal Pharmaceuticals announced earlier on Friday that it has received three new U.S. patents for its lead drug, Rezdiffra. 


Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH

Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH PR Newswire SUZHOU, China and MLNDAL, Sweden, July 1, 2026 SUZHOU, China and MLNDAL, Sweden, July 1, 2026 /PRNewswire...

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of therapeutics for metabolic dysfunction-associated steatohepatitis. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.

Madrigal Pharmaceuticals Inc

Neutral Sentiment

<ul class="summary-bullets"><li>Wells Fargo said competition down the line could limit the long-term commercial potential of its therapy for treatment-resistant depression.</li><li>The firm initiated Helus Pharma with an ‘Overweight’ rating and a $16 price target, a near 100% upside potential from current levels.</li><li>Wells Fargo forecasts more than $7 billion in peak sales for Madrigal Pharmaceuticals’ Rezdiffra.</li></ul>Wells Fargo initiated coverage on five biotechnology companies, expressing optimism on several late-stage drug developers focused on depression therapies, including Helus Pharma (HELP), GH Research (GHRS), and Definium Therapeutics (DFTX), while taking a more cautious stance on Compass Pathways (CMPS).<h2 class="st-heading-2">Compass Could Face Competitive Challenges</h2>According to The Fly, Wells Fargo initiated Compass Pathways with an ‘Equal Weight’ rating and a $13 price target, implying a 12% upside potential from current levels.&nbsp;<a href="https://stocktwits.com/symbol/CMPS">CMPS stock</a> was up 2.6% at the time of writing.Analyst Benjamin Burnett said the company’s COMP360 therapy for treatment-resistant depression is likely to meet the U.S. Food and Drug Administration’s (FDA) approval standard after two positive Phase 3 studies. The latest trial, reported in February 2026, showed that two 25 mg doses of COMP360 delivered a statistically significant and clinically meaningful reduction in depression symptom severity, measured by the Montgomery–Åsberg Depression Rating Scale (MADRS), compared with the 1 mg dose.However, he noted that the treatment’s efficacy appears comparable to Johnson &amp; Johnson’s Spravato, while competition from follow-on therapies could limit its long-term commercial opportunity.Retail sentiment for CMPS on Stocktwits turned ‘bearish’ from ‘neutral’ a day earlier. The stock has seen strong buying interest so far this year, gaining more than 76%.<h2 class="st-heading-2">HELP Stock Has Attractive Risk/Reward Profile Ahead Of Phase 3 Results</h2>Wells Fargo initiated Helus Pharma with an ‘Overweight’ rating and a $16 price target, a near 100% upside potential from current levels.The firm thinks COMP360 data provide validation for Helus’ HLP003 in treatment-resistant depression.&nbsp;<a href="https://stocktwits.com/symbol/HELP">HELP stock</a> was up around 5% at the time of writing.Last week, Helus Pharma completed enrollment in its Phase 3 Approach Trial evaluating HLP003 in adults with moderate to severe major depressive disorder who have not responded adequately to antidepressants. The company expects to report Phase 3 results in the fourth quarter.The firm sees an attractive risk-reward profile for the shares ahead of the topline results.Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, amid ‘extremely high’ message volumes. The stock has shed roughly 3% so far this year.<h2 class="st-heading-2">Wells Fargo Is Bullish On GH Research Despite Investor Skepticism</h2>The firm started GH Research with an ‘Overweight’ rating and a $44 price target, implying a 56% upside potential from its current levels.&nbsp;<a href="https://stocktwits.com/symbol/GHRS">GHRS stock</a> is up around 3.2%.In June, the company reported results of a Phase 2a trial for postpartum depression. The treatment met its primary endpoint, reducing depression scores by an average of 35.4 points by Day 8. The treatment was well tolerated, with no serious adverse events or treatment-related suicidal thoughts or behavior.Despite an over 12% increase in the stock price since then, Wells Fargo said the current valuation suggests investors remain unconvinced that the company’s encouraging Phase 2b depression data will be replicated in Phase 3 trials.The stock has gained more than 112% so far this year, while its retail sentiment on Stocktwits turned ‘neutral’ from ‘bullish’ a day earlier.<h2 class="st-heading-2">Definium Therapeutics Is Riding The Psychiatry Trend</h2>Wells Fargo also started coverage of Definium Therapeutics with an ‘Overweight’ rating and a $68 price target, indicating a 51% upside potential. The stock is currently up around 4%.The firm believes Spravato has validated the interventional psychiatry model for treating depression, creating room for new therapies.Definium’s lead candidate, DT120, met the primary endpoint in its Phase 3 Emerge trial in adults with major depressive disorder. Patients treated with DT120 saw a 13.3-point reduction in depression scores at six weeks, compared with a 5.2-point reduction in the placebo group. Wells Fargo believes the company is well positioned to benefit from growing demand for innovative mental health treatments.<a href="https://stocktwits.com/symbol/DFTX">DFTX shares</a> have gained more than 240% so far this year, while retail sentiment on Stocktwits has remained in the ‘bearish’ territory over the past 24 hours.<h2 class="st-heading-2">Madrigal’s Rezdiffra Has A Multi-billion-Dollar Sales Potential</h2>The firm launched coverage of Madrigal Pharmaceuticals with an ‘Overweight’ rating and a $685 price target, representing a 22% upside potential, while its stock is currently up around 3%.Wells Fargo forecasts more than $7 billion in peak sales for Rezdiffra, its lead medication to treat noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis.The firm also added that physician surveys indicate concerns about GLP-1 drugs and competitive pressures are overstated, supporting durable growth in what it expects to be a ‘multi-drug market.’Retail sentiment surrounding&nbsp;<a href="https://stocktwits.com/symbol/MDGL">MDGL</a> turned ‘bullish’ from ‘neutral’ a day earlier. The stock is down around 6% so far this year.Also read:<a href="https://stocktwits.com/news-articles/markets/equity/capr-stock-is-crashing-today-fda-briefing-casts-doubt-on-duchenne-cell-therapy-before-key-vote/cZZx1IOR76P">&nbsp;CAPR Stock Is Crashing Today – FDA Briefing Casts Doubt On Duchenne Cell Therapy Before Key Vote</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

While Johnson & Johnson’s stock (JNJ) has risen 25.6% so far in 2025, Roche’s U.S.-listed stock (RHHBY) has gained 20% over the same period. (Photo credit: Getty Images)

Wells Fargo began coverage on five biotech stocks on Monday, with only Compass Pathways receiving an ‘Equal-Weight’ rating while the rest received ‘Overweight’ ratings.

Definium Therapeutics Inc.

GH Research PLC

Helus Pharma Inc.

Tema Neuroscience & Mental Health ETF

AdvisorShares Psychedelics ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$457.96
Prev Close	$467.54
Open	$467.90
Dividend Yield	0.00%
50-Day Moving Average	$510.68
Beta	0.84
Avg. Volume	225,384.34
PE Ratio	-35.54

52-Week High	$615.00
52-Week Low	$393.61
Market Capitalization	$10.8B
EPS (Annual)	-$12.85
Price to Book	20.19
Revenue Per Employee	$1.05M

Feed

News

Sentiment

Earnings

Fundamentals

Info

MDGL Fundamentals